Drug Trial Radar · NCT04541186
Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia
Last checked: Nov 19, 2026Latest source record: Jul 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
86
Actual
Start
Sep 1, 2020
Primary completion
May 19, 2022
Study completion May 31, 2022
Sponsor
- Lead sponsor
- 89bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to assess the efficacy, safety, and tolerability of different doses and dose regimens (once weekly \[QW\] or every 2 weeks \[Q2W\]), subcutaneous (SC) dosing of BIO89-100 (pegozafermin) compared to placebo in participants with severe hypertriglyceridemia (SHTG).
Conditions
- Severe Hypertriglyceridemia
Interventions
PegozaferminDrug
Subcutaneous injection
PlaceboDrug
Matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline to Week 8 in Serum Triglyceride (TG)Time frame: Baseline, Week 8
Locations
48 sites in 4 countries. Site status is shown where the registry gives one.
89Bio Clinical Study Site
La Mesa, California
89Bio Clinical Study Site
San Francisco, California
89Bio Clinical Study Site
Clearwater, Florida
89Bio Clinical Study Site
Greenacres City, Florida
89Bio Clinical Study Site
Jacksonville, Florida
89Bio Clinical Study Site
Miami, Florida
89Bio Clinical Study Site
Miami, Florida
89Bio Clinical Study Site
Miami Lakes, Florida
89Bio Clinical Study Site
Miami Lakes, Florida
89Bio Clinical Study Site
North Miami Beach, Florida
89Bio Clinical Study Site
Orlando, Florida
89Bio Clinical Study Site
Tampa, Florida
89Bio Clinical Study Site
Lawrenceville, Georgia
89Bio Clinical Study Site
Quincy, Illinois
89Bio Clinical Study Site
Wauconda, Illinois
89Bio Clinical Study Site
West Des Moines, Iowa
89Bio Clinical Study Site
Louisville, Kentucky
89Bio Clinical Study Site
Olive Branch, Mississippi
89Bio Clinical Study Site
Albany, New York
89Bio Clinical Study Site
Greensboro, North Carolina
89Bio Clinical Study Site
Morganton, North Carolina
89Bio Clinical Study Site
Marion, Ohio
89Bio Clinical Study Site
Summerville, South Carolina
89Bio Clinical Study Site
Chattanooga, Tennessee
89Bio Clinical Study Site
Kingsport, Tennessee
89Bio Clinical Study Site
Austin, Texas
89Bio Clinical Study Site
Dallas, Texas
89Bio Clinical Study Site
Dallas, Texas
89Bio Clinical Study Site
Houston, Texas
89Bio Clinical Study Site
Lampasas, Texas
89Bio Clinical Study Site
Magnolia, Texas
89Bio Clinical Study Site
Manassas, Virginia
89Bio Clinical Study Site
Pardubice, Czechia
89Bio Clinical Study Site
Prague, Czechia
89Bio Clinical Study Site
Prague, Czechia
89Bio Clinical Study Site
Prague, Czechia
89Bio Clinical Study Site
Prague, Czechia
89Bio Clinical Study Site
Baja, Hungary
89Bio Clinical Study Site
Békéscsaba, Hungary
89Bio Clinical Study Site
Budapest, Hungary
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.